Stock 9939 KINTOR PHARMACEUTICAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Kintor Pharmaceutical Limited Stock

Equities

9939

KYG5273B1077

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
0.96 HKD +2.13% Intraday chart for Kintor Pharmaceutical Limited +10.34% -41.10%
Apr. 22 Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint CI
Apr. 22 Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment MT

Financials

Sales 2023 - Sales 2024 * 103M 14.21M 111M Capitalization 398M 54.88M 430M
Net income 2023 -1.06B -146M -1.15B Net income 2024 * -800M -110M -864M EV / Sales 2023 -
Net Debt 2023 * 589M 81.29M 636M Net cash position 2024 * - 0 0 EV / Sales 2024 * 3.86 x
P/E ratio 2023
-0.6 x
P/E ratio 2024 *
-0.5 x
Employees 225
Yield 2023 *
-
Yield 2024 *
-
Free-Float 80.37%
More Fundamentals * Assessed data

Chart Kintor Pharmaceutical Limited

Dynamic Chart

Latest news about Kintor Pharmaceutical Limited

Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint CI
Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment MT
Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Kintor Pharmaceutical's Trial of Androgenetic Alopecia Drug Cleared by Chinese Regulator MT
Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA CI
Kintor Pharmaceutical's Phase 3 Trial for Alopecia Treatment Promotes Hair Growth; Shares Plunge 30% MT
Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia CI
Kintor Pharmaceutical Limited Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China CI
Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Kintor Pharmaceutical Completes Enrollment for Alopecia Drug Trial MT
Kintor Pharma Announces Completion of Patient Enrollment in Phase Ii Clinical Trial of Gt20029 for Treatment of Androgenetic Alopecia in China CI
Kintor Pharmaceutical Enrolls First Patient for Phase III of Alopecia Drug Trial MT
Kintor Pharmaceutical Limited Announces Completion of First Patient Enrollment in Long-Term Safety Trial of Kx-826 CI
Kintor Pharmaceutical Limited Appoints Ming Ming Cheung as Joint Company Secretary CI
Kintor Pharmaceutical's Completes US Phase 2 Trials of Alopecia Treatment; Shares Fall 4% MT
More news

Analyst Recommendations on Kintor Pharmaceutical Limited

Kintor Proxalutamide's Covid-19 Clinical Trial Shows Significant Reduction in Hospitalization and Ventilation Rates CI
More recommendations

Press releases Kintor Pharmaceutical Limited

Kintor Pharmaceutical : Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine PU
Kintor Pharmaceutical : Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China PU
Kintor Pharmaceutical : Pharma Announces 2023 Interim Results and Recent Business Highlights PU
Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China PU
Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA AQ
More press releases

Quotes and Performance

1 day+2.13%
1 week+10.34%
Current month+11.63%
1 month+14.29%
3 months-23.81%
6 months-64.96%
Current year-41.10%
More quotes

Highs and lows

1 week
0.92
Extreme 0.92
1.11
1 month
0.81
Extreme 0.81
1.11
Current year
0.81
Extreme 0.81
1.98
1 year
0.81
Extreme 0.81
5.83
3 years
0.81
Extreme 0.81
89.00
5 years
0.81
Extreme 0.81
89.00
10 years
0.81
Extreme 0.81
89.00
More quotes

Managers and Directors - Kintor Pharmaceutical Limited

Managers TitleAgeSince
You Zhi Tong CEO
 Chief Executive Officer - 09-03-23
Ming Ming Cheung DFI
 Director of Finance/CFO 47 21-08-31
Zhi Hua Ren CTO
 Chief Tech/Sci/R&D Officer - 20-09-30
Members of the board TitleAgeSince
Wei Peng Gao BRD
 Director/Board Member 49 21-06-21
Cheng Wei Liu BRD
 Director/Board Member 54 22-05-04
You Zhi Tong CEO
 Chief Executive Officer - 09-03-23
More insiders

ETFs positioned on Kintor Pharmaceutical Limited

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
0.58% 4 M€ -27.92%
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
0.02% 2 M€ -.--%
BMO MSCI INNOVATION INDEX ETF - CAD ETF BMO MSCI Innovation Index ETF - CAD
0.01% 7 M€ -.--% -
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.00% 117 M€ +1.11% -
More ETFs positioned on Kintor Pharmaceutical Limited

Quotes

Date Price Change Volume
24-04-26 0.96 +2.13% 1,475,000
24-04-25 0.94 -1.05% 518,000
24-04-24 0.95 -1.04% 1,240,000
24-04-23 0.96 -5.88% 2,471,000
24-04-22 1.02 +17.24% 7,232,000

Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am EDT

More quotes

Company Profile

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China. The Company is focused on the research and development of drugs for cancers and other androgen receptor (AR) related diseases. Its primary drug candidate is Proxalutamide which is in phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). The Company are also developing other drug candidates, including a phase II small molecule drug candidate Pyrilutamide, a phase II monoclonal antibody drug candidate ALK-1, a phase I mTOR inhibitor drug candidate Detorsertib and an inhibitor of the hedgehog signal translation pathway GT1708F.
Sector
Biotechnology & Medical Research
Calendar
2024-08-22 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8886 CNY
Average target price
13.21 CNY
Spread / Average Target
+1,386.53%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
KINTOR PHARMACEUTICAL LIMITED Stock Kintor Pharmaceutical Limited
-41.10% 54.88M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 9939 Stock